Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1992 Nov 30;189(1):296-303.
doi: 10.1016/0006-291x(92)91557-7.

Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization

Affiliations
Comparative Study

Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization

J R Pisegna et al. Biochem Biophys Res Commun. .

Abstract

The receptors for the brain and gastrointestinal peptide, cholecystokinin, can be classified into CCKA and CCKB subtypes. Having recently cloned the rat CCKB receptor, we used it's cDNA to isolate the human CCKB receptor homologue from brain and stomach which encodes a 447 amino acid protein with 90% identity to both rat CCKB and canine gastrin receptors. Northern hybridization identifies transcripts from stomach, pancreas, brain and gallbladder. The CCKB receptor gene maps to chromosome 11. Expression of the receptor cDNA in COS-7 cells was characteristic of a CCKB receptor subtype pharmacology. These data confirm that we have cloned a novel gene for the human brain and stomach CCKB receptor.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Nucleotide and deduced amino acid sequences of the human brain and stomach CCKB receptor cDNA clone. The solid lines labelled with Roman numerals I-VII delineate the putative transmembrane domains predicted by the Kyte-Doolittle criteria (31) and homology with the rat CCKB as well as other G-protein-coupled receptor superfamily members. The solid triangles indicate three potential sites for N-linked glycosylation. The solid underlines indicate potential sites for serine and threonine phosphorylation (25). The AATAAA cleavage and polyadenyalation sequence is underlined. Solid circles indicate cysteine residues which are potential sites for either disulfide bridge formation (26,27,28) (residues 127 and 205) or palmitoylation (29,30) (residue 408).
FIG. 2.
FIG. 2.
Alignment of the human CCKB receptor (HUCCKBR), rat CCKB receptor (RATCCKBR) and canine gastrin receptor (CANGASR) deduced protein sequences. Using the “Pileup” program sequence analysis package of the Genetics Computer Group (21) the human CCKB receptor was aligned for maximal homology with the rat CCKB receptor and the canine gastrin receptor. Shown here using amino acid acid letter symbols is the result of this alignment with solid lines indicating putative transmembrane domains and boxed letters indicating amino acids from rat and dog not conserved in the human receptor sequence.
FIG. 3.
FIG. 3.
Northern blot analysis of poly (A)+ RNA from the human organs. Two micrograms of poly (A)+ RNA from human brain, stomach, pancreas, and gallbladder were separated on a 1.5% denaturing/formaldehyde agarose gel and probed under conditions of high stringency with the coding region of the CCKB receptor cDNA labelled with [32P] by random primer extension. The blot was exposed for 48 hours and scanned with a phosphorimager (Molecular Dynamics). The lines on the left correspond to the migration Positions of the 28S and 18S ribosomal RNA.
FIG. 4.
FIG. 4.
Ability of CCK receptor agonists and antagonists to inhibit binding of [125I]BH-CCK-8 to COS-7 cells expressing the human CCKB receptor. COS-7 cells were transfected with the mammalian expression vector, pCDL-SRα, containing the human CCKB receptor cDNA. Transfected COS-7 cells were incubated with either the tracer alone or increasing concentrations of agonists CCK-8 or gastrin-17-I (left panel) or antagonists L-365,260 and L-364,718 (right panel). Data are presented as percent saturable binding (total binding in the presence of labelled hormone alone minus binding in the presence of 1 μM CCK-8).

References

    1. Hill DR, Campbell NJ, Shaw TM, and Woodruff GN (1987) J. Neurosci 7, 2967–2976. - PMC - PubMed
    1. Jensen RT, Wank SA, Rowley WH, Sato S, and Gardner JD (1989) Trends Pharmacol. Sci 10, 418–423. - PubMed
    1. Saito A, Sankaran H, Goldfine ID, and Williams JA (1980) Science 1155–l156. - PubMed
    1. Moran TH, Robinson PH, Goldrich MS, and McHugh PR (1975) Brain Research 362, 986–989. - PubMed
    1. Chang RSL, and Lotti VJ (1986) Proc. Natl. Acad. Sci 834923–4926. - PMC - PubMed

Publication types

MeSH terms